Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination with Azacitidine in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)

Sub-indication: Hematologic Malignancies

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Innovent Biologics, Inc

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.